Protective effect of ganoderan on renal damage in rats with chronic glomerulonephritis.
OBJECTIVE
To investigate the protective effect of ganoderan on renal damage in rat models with chronic glomerulonephritis induced by adriamycin.


METHODS
48 healthy Sprague-Dawley rats were randomly divided into three groups: control, nephritic model and ganoderan treatment groups. Changes of the following indices in the three groups were observed 6 weeks after treatment: 24-hour urine protein, albumen, serum creatinine, cholesterol. Histopathological observations of the renal cortex were made by light and electron microscopy.


RESULTS
Compared with controls, levels of 24-hour urine protein (9.60+/-0.57 mg/d vs. 82.50+/-3.18 mg/d), serum creatinine (35.25+/-2.63 micromol/L vs. 44.75+/-8.06 micromol/L) and cholesterol (1.15+/-0.10 mmol/L vs. 4.02+/-0.25 mmol/L) of rats in the nephritic model group were increased (P < 0.05), and the concentration of albumen was decreased (35.98+/-1.34 g/L vs. 19.05+/-0.62 g/L, P < 0.05). Ganoderan administration decreased 24-hour urine protein (82.50+/-3.18 mg/d vs. 45.01+/-3.94 mg/d, P < 0.05). Following ganoderan, the pathological changes in kidney tissue were improved compared with those in the nephritic model group.


CONCLUSIONS
Ganoderan exerts protective effects in rats with chronic glomerulonephritis induced by ADR. Ganoderan reduced 24-hour urine protein, serum creatinine, cholesterol, improving renal function and reducing the severity of renal injury.
Zhong
Wei-De
WD
Guangzhou First Municipal People's Hospital, Affiliated Guangzhou Medical College, Guangzhou 510180, China. wdezhong@21cn.com
He
Hui-Chan
HC
Ou
Ru-Biao
RB
Bi
Xue-Cheng
XC
Dai
Qi-Shan
QS
Han
Zhao-Dong
ZD
Liang
Yu-Xiang
YX
Ye
Yong-Kan
YK
Qin
Wei-Jun
WJ
Li
Ze
Z
Zeng
Guo-hua
GH
Zhu
Gang
G
D000419:Albuminuria / Q000652:urine; D000818:Animals; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D007150:Immunohistochemistry; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D007677:Kidney Function Tests; D008854:Microscopy, Electron; D011134:Polysaccharides / Q000627:therapeutic use*; D011507:Proteinuria / Q000652:urine*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D013997:Time Factors
D011134:Polysaccharides; D002784:Cholesterol; C047407:ganoderan B; D003404:Creatinine